Seikagaku
Tokyo, Japan· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
Japanese glycoscience pioneer developing hyaluronic acid-based therapeutics for ophthalmology and orthopedics, with commercial products and late-stage pipeline.
OphthalmologyOrthopedics
Technology Platform
Glycoscience platform specializing in hyaluronic acid and chondroitin sulfate chemistry for therapeutic and medical device applications.
Opportunities
Expansion into U.S.
market with SI-6603 approval, growing demand for hyaluronic acid-based medical products in aging populations, and potential new applications from glycoscience research.
Risk Factors
Regulatory delays for SI-6603, competition in hyaluronic acid markets, dependence on Japanese market, and pricing pressures on bulk products.
Competitive Landscape
Competes with large pharmaceutical companies in ophthalmology and orthopedics markets, as well as specialized players in glycosaminoglycan production; differentiates through deep glycoscience expertise and vertical integration from bulk materials to finished products.